Stephen L Warren
Physician at Westfield Ct, Fort Collins, CO

2011013, Jun 9, 2011

Mar 19, 2008

12/531825

William D. Dalke - Aurora CO, US
Michael J. Gerber - Denver CO, US
Kevin Lillehei - Englewood CO, US
James E. Matsuura - Fort Collins CO, US
Stephen L. Warren - Fort Collins CO, US

Peak Biosciences Inc. - Fort Collins CO

A61K 51/00, A61P 35/00, B23P 11/00

424 113, 137 1501

Methods are provided for the local radiotherapy of cancers such as locally invasive, advanced stage solid tumors, and normal tissues penetrated by processes of cancerous tissue, through administration of Auger-electron emitting radionucleoside analogs using high-flow microinfusion techniques (“convection-enhanced delivery”). Direct infusion under pressure, at flow rates in excess of at least about 0.5 microliters/min of the radionucleosides provides for their mass transport through tissue to a much higher degree than could be achieved by passive, unpressurized diffusion. The unique properties of these radionucleoside analogs that provide for surprisingly effacacious delivery by high-flow microinfusion include rapid clearance from tissues following local injection without the benefit of sustained high-flow microinfusion, rapid and complete clearance via the blood stream, poor permeation of barriers such as the blood-brain barrier, and a highly potent, non-selective, but very short range killing effect on cells that are undergoing DNA replication that incorporate radionucleosides into their chromosomes.

8470295, Jun 25, 2013

May 9, 2008

12/599594

Stephen L. Warren - Fort Collins CO, US
James E. Matsuura - Fort Collins CO, US
Michael J. Gerber - Denver CO, US

Peak Biosciences, Inc. - Fort Collins CO

A61K 51/00, A61K 38/00, A61P 5/24, A61P 35/00

424 173, 514 102, 514 195

A method is provided for treatment of disorders involving hyperproliferative cells, such as malignancies, advanced stage solid tumors like glioblastoma multiforme, and non-malignant hyperproliferative pathological conditions such as adult macular degeneration. A short range, unselective cell killing radiotherapeutic substance is administered, optionally in a spatially defined volume of tissue, optionally in combination with a mitogenic agent that stimulates or induces DNA biosynthesis. In this way, the percentage of hyperproliferative that are susceptible to killing by the radiotherapeutic agent is increased. Cancer stem cells can be induced to enter S phase with the mitogenic agent, then killed with the radiotherapeutic agent. Thus, not only does the combination effectively kill the transit amplifying cell population, the most rapidly replicating type of cell in a tumor, but it also effectively kills the tumor stem cells, which give rise to the transit amplifying cells, for a longer lasting anticancer effect.

2009009, Apr 9, 2009

Dec 15, 2005

11/793296

Stephen L. Warren - Fort Collins CO, US
Eric Dadey - Furlong PA, US
Richard L. Dunn - Fort Collins CO, US
John Milton Downing - Fort Collins CO, US
Ellen Qi Li - Ft. Collins CO, US

A61K 9/00, A61K 38/08, A61P 3/10, A61P 35/00

424422, 514 16

The present invention relates to an octreotide sustained release delivery system for treatment of diseases relating to somatotropin and/or somatostatin. The sustained release delivery system of the invention includes a flowable composition containing an octreotide compound, and an implant containing the octreotide compound. The flowable composition may be injected into tissue whereupon it coagulates to become the solid or gel, monolithic implant. The flowable composition includes a biodegradable, thermoplastic polymer, an organic liquid and an octreotide compound.

2009030, Dec 10, 2009

Jul 6, 2007

12/375349

Stephen L. Warren - Fort Collins CO, US
Gregory A. Gould - Wrentham MA, US
Kevin Lillehei - Englewood CO, US

A61K 51/12, A61K 9/00, A61P 35/00, A61K 49/06

424 111, 424423, 424426, 424 93

A filament comprising a biocompatible material and a bioactive agent, adapted for implantation within the tissue of a patient wherein the bioactive agent is released over a period of time, is provided. An array of a plurality of the filaments implanted within the tissue of a patient, an array assembler, and a matrix comprising a plurality of filaments and a base adapted for implantation within the tissue of a patient, are further provided. A method for treatment of a malcondition in a patient comprises implantation of a filament, an array of filaments, or a matrix. The bioactive agent can be a chemotherapeutic agent or a radiotherapeutic agent. A radiotherapeutic agent is 123I- or 125I-IUDR, for example in treatment of an advanced stage localized brain tumor such as glioblastoma multiforme.

7005260, Feb 28, 2006

Jan 28, 2000

10/031193

Brian Hicke - Boulder CO, US
Stephen Warren - Fort Collins CO, US
David Parma - Boulder CO, US
Larry Gold - Boulder CO, US

Gilead Sciences, Inc. - Foster City CA

C12Q 1/68, C07H 21/04, C12P 19/34

435 6, 435 71, 435 911, 536 231, 536 243, 536 253, 536 265

Methods are described for the identification and preparation of nucleic acid ligands to tenascin-C. Included in the invention are specific RNA ligands to tenascin-C identified by the SELEX method. Further included in the invention are methods for detecting the presence of a disease condition in a biological tissue in which tenascin-C is expressed.

2006021, Sep 21, 2006

Oct 4, 2005

11/244438

Eric Dadey - Fort Collins CO, US
Christopher Lindemann - Loveland CO, US
Stephen Warren - Fort Collins CO, US
Richard Norton - Ft. Collins CO, US

A61F 2/00

424427000, 424428000

The present invention provides a flowable composition suitable for use as a controlled release implant. The flowable composition can be administered into the ocular region of a mammal. The composition includes: (a) a biodegradable, biocompatible thermoplastic polymer that is at least substantially insoluble in aqueous medium, water or body fluid; (b) a biological agent, a metabolite thereof, a biological agently acceptable salt thereof, or a prodrug thereof; and (c) a biocompatible organic liquid, at standard temperature and pressure, in which the thermoplastic polymer is soluble. The present invention also provides methods of medical treatment that include administering the flowable composition into the ocular region of a mammal.

8600479, Dec 3, 2013

Mar 20, 2008

12/531808

William D. Dalke - Aurora CO, US
Kevin Lillehei - Englewood CO, US
Thomas A. Jellison - Coventry RI, US
Michael J. Gerber - Denver CO, US
James E. Matsuura - Fort Collins CO, US
Stephen L Warren - Fort Collins CO, US

Peak Biosciences, Inc. - Fort Collins CO

A61B 5/05

600424, 600433, 600434, 600435, 600466

A catheter system adapted for navigating, guiding and implanting a catheter or a plurality of catheters in a spatially-defined implantation within the tissue of a patient is provided. The system can include a tissue navigation system and a probe to inform the navigation system to guide emplacement of the catheters within a target tissue. The probe can provide images, such as fiberoptic visual images, or ultrasound images, or can provide radiolocation data, to guide the catheter emplacement. The catheters supply a pressurized liquid including a bioactive agent, such as can be used in the treatment of cancer, for example 123I- or 125I-IUDR. The system and methods provided can be used in the treatment of locally advanced tumors, such as cancers of the brain, head or neck, esophagus, prostate, ovary, liver, pancreas, bladder or rectum.

2007023, Oct 4, 2007

Mar 28, 2007

11/692624

Stephen L. Warren - Fort Collins CO, US

A61K 38/21, A61K 39/04

424 857, 4242481

Novel methods and drug products for treating superficial bladder cancer (SBC) are disclosed, which involve parenteral administration of low doses of a type 1 interferon. The doses used are subtherapeutic for other solid tumors. Use of the novel methods and products in combination with other therapies for SBC is also described.

2008026, Oct 30, 2008

Jun 24, 2008

12/215101

Stephen L. Warren - Fort Collins CO, US
David W. Osborne - Fort Collins CO, US
Richard Holl - Park City UT, US

QLT USA, INC. - Fort Collins CO

A61K 9/70, A61K 31/403, A61K 31/4523

424428, 514411, 514415, 514323

The present invention provides bioerodible, water-soluble pharmaceutical carriers for ocular (e.g., transconjunctival or transcorneal) delivery of pharmaceuticals for either systemic or local therapy.

2005001, Jan 20, 2005

Nov 12, 2003

10/706603

Stephen Warren - Fort Collins CO, US
David Osborne - Santa Rosa CA, US
Richard Holl - Fort Collins CO, US

A61F006/06

424430000

The present invention provides bioerodible, water-soluble pharmaceutical carriers for ocular (e.g., transconjunctival or transcorneal) delivery of pharmaceuticals for either systemic or local therapy.